Patents by Inventor Philippe Durette

Philippe Durette has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Nucleoside derivatives as inhibitors of rna-dependent rna viral polymerase
    Publication number: 20070004669
    Abstract: The present invention provides nucleoside compounds and certain derivatives thereof which are inhibitors of RNA-dependent RNA viral polymerase. These compounds are inhibitors of RNA-dependent RNA viral replication and are useful for the treatment of RNA-dependent RNA viral infection. They are particularly useful as inhibitors of hepatitis C virus (HCV) NS5B polymerase, as inhibitors of HCV replication, and/or for the treatment of hepatitis C infection. The invention also describes pharmaceutical compositions containing such nucleoside compounds alone or in combination with other agents active against RNA-dependent RNA viral infection, in particular HCV infection. Also disclosed are methods of inhibiting RNA-dependent RNA polymerase, inhibiting RNA-dependent RNA viral replication, and/or treating RNA-dependent RNA viral infection with the nucleoside compounds of the present invention.
    Type: Application
    Filed: June 17, 2003
    Publication date: January 4, 2007
    Inventors: Steven Carroll, David Olsen, Philippe Durette, Balkrishen Bhat, Prasad Dande, Anne Eldrup
  • Substituted 2-aminopyridines as inhibitors of nitric oxide synthase
    Patent number: 5972975
    Abstract: Substituted 2-aminopyridine compounds of Formula (I) and pharmaceutically acceptable salts which have been found useful in the treatment of nitric oxide synthase mediated diseases and disorders.
    Type: Grant
    Filed: May 22, 1997
    Date of Patent: October 26, 1999
    Assignee: Merck & Co., Inc.
    Inventors: Craig Esser, William Hagmann, William Hoffman, Shrenik Shah, Kenny Wong, Renee Chabin, Ravindra Guthikonda, Malcolm Maccoss, Charles Caldwell, Philippe Durette
  • Substituted azetidinones as anti-inflammatory and antidegenerative agents
    Patent number: 5952321
    Abstract: New substituted azetidinones of the general Formula (I) which have been found to be potent elastase inhibitors and thereby useful anti-inflammatory and antidegenerative agents are described, wherein n is
    Type: Grant
    Filed: December 12, 1996
    Date of Patent: September 14, 1999
    Assignee: Merck & Co., Inc.
    Inventors: James Doherty, Conrad Dorn, Philippe Durette, Paul Finke, Malcolm Maccoss, Sander Mills, Shrenik Shah, Soumya Sahoo, William Hagmann, Scott Polo
  • Heteroaryl spiroethercycloalkyl tachykinin receptor antagonists
    Patent number: 5929094
    Abstract: The present invention is directed to certain novel compounds represented by structural formula I: ##STR1## or a pharmaceutically acceptable salt thereof, wherein R.sup.3, R.sup.6, R.sup.7, R.sup.8, R.sup.11, R.sup.12, R.sup.13, A, m, n and the dashed lines are defined herein. The invention is also concerned with pharmaceutical formulations comprising these novel compounds as active ingredients and the use of the novel compounds and their formulations in the treatment of certain disorders. The compounds of this invention are tachykinin receptor antagonists and are useful in the treatment of inflammatory diseases, pain or migraine, asthma and emesis.
    Type: Grant
    Filed: October 22, 1997
    Date of Patent: July 27, 1999
    Assignee: Merck & Co., Inc.
    Inventors: Philippe Durette, Ihor Kopka, Malcolm MacCoss, Sander Mills
  • Substituted 2-acylamino-pyridines as inhibitors of nitric oxide synthase
    Patent number: 5908842
    Abstract: Substituted 2-acylaminopyridine compounds and pharmaceutically acceptable salts which have been found useful in the treatment of nitric oxide synthase mediated diseases and disorders.
    Type: Grant
    Filed: May 20, 1997
    Date of Patent: June 1, 1999
    Assignee: Merck & Co., Inc.
    Inventors: Ravindra Guthikonda, William Hagmann, Malcolm Maccoss, Shrenik Shah, Philippe Durette
  • Substituted azetidiones as anti-inflammatory and antidegenerative agents
    Patent number: 5747485
    Abstract: Substituted azetidinones are herein disclosed for use in the treatment of various elastase-mediated diseases.
    Type: Grant
    Filed: June 5, 1997
    Date of Patent: May 5, 1998
    Assignee: Merck & Co., Inc.
    Inventors: James Doherty, Conrad Dorn, Philippe Durette, Paul Finke, Malcolm Maccoss, Sander Mills, Shrenik Shah, Soumya Sahoo, William Hagmann, Jeffrey Hale, Thomas Lanza
  • Carboxy-peptidyl derivatives as antidegenerative active agents
    Patent number: 5672583
    Abstract: Novel Carboxy-peptidyl compounds of Formula I are found to be useful inhibitors of matrix metalloendoproteinase-mediated diseases including osteoarthritis, rheumatoid arthritis, septic arthritis, tumor invasion in certain cancers, periodontal disease, corneal ulceration, proteinuria, dystrophobic epidermolysis bullosa, coronary thrombosis associated with atherosclerotic plaque rupture, and aneurysmal aortic disease. The matrix metalloendoproteinases are a family of zinc-containing proteinases including but not limited to stromelysin, collagenase, and gelatinase, that are capable of degrading the major components of articular cartilage and basement membranes. The inhibitors claimed herein may also be useful in preventing the pathological sequelae following a traumatic injury that could lead to a permanent disability. These compounds may also have utility as a means for birth control by preventing ovulation or implantation.
    Type: Grant
    Filed: May 17, 1995
    Date of Patent: September 30, 1997
    Assignee: Merck & Co., Inc.
    Inventors: Kevin Chapman, William Hagmann, Philippe Durette, Craig Esser, Ihor Kopka, Charles Caldwell